Kalgut tablets 10 mg for chronic heart failure (Denopamine)
Product Code :
Availability : 11
General information on Japanese Kalgut tablets 10 mg for chronic heart failure (Denopamine)
Package details: 100 tablets
Manufacturer: Mitsubishi Tanabe Pharma Corporation, Japan
Active ingredient: denopamine (chemic formula C18H23NO4)
Medical effect: Kalgut tablets are effective for the treatment of chronic heart failure
Contraindications and precautions: do not use for pregnant and breastfeeding women.
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Kalgut tablets 10 mg from Japan for chronic heart failure (Denopamine)
For adults, take 5 to 10 mg of the active ingredient at a time, 3 times a day. Please note that these tablets contain 10 mg of the active ingredient in a tablet. The dosage may be adjusted by the consulting doctor according to the age or symptoms. In many cases, these tablets are prescribed together with other medicines (digitalis, diuretic, vasodilator etc.).
How effective are Japanese Kalgut tablets 10 mg for chronic heart failure (Denopamine)?
Kalgut tablets contain denopamine, a β1 adrenergic receptor agonist that works as cardiotonic. It provides the following effects:
- stimulates pumping function of the heart,
- increases cardiac output,
- relieves vasospastic angina pectoris symptoms,
- increases myocardial oxygen consumption,
- increases coronary blood flow.
As the result, Kalgut tablets help to treat angina pectoris and congestive heart failure.
Who should take Kalgut tablets 10 mg from Japan?
Denopamine works effective even for patients who are refractory to the treatment with other β1 adrenergic receptor agonists like prazosin or nicorandil (D. Nakajima, N. Negoro et al. "Effectiveness of low dose denopamine, a beta1-adrenoceptor agonist, in a patient with vasospastic angina refractory to intensive medical treatment". International Journal of Cardiology, 2006, April, 108 (2): 281–283). It differs from other medicines being very selective. Denopamine has no inhibitory effect on the phosphodiesterase, exerts its inotropic effect with little formation of cyclic-AMP and minimally stimulates adenylate cyclase. That means that denopamine is less likely to cause desensitization of β1 adrenergic receptors. That’s why Kalgut tablets from Japan can be used for the long-term treatment.